Unique Cabozantinib Dosing Considerations in People Living with HIV and Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37792442.
- Also identified by DOI 10.1158/1078-0432.CCR-23-2351.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A recent article characterized dosing recommendations for cabozantinib in people living with HIV (PLWH) and cancer, a group that is often excluded from clinical trials. This study suggests cabozantinib is effective in cancers disproportionately impacting PLWH and has translational implications for the design of studies evaluating drug-drug interactions. See related article by Haigentz et al., p. 5038.
Medical subject headings
- HIV Infections
- Neoplasms